Overview

Study of CPI-100 in Patients With Advanced Tumors

Status:
Recruiting

Trial end date:
2021-12-21

Target enrollment:

Participant gender:

Summary

This is a prospective, open-label, 2-arm, non-randomized study of CPI-100 in patients with advanced tumors. CPI-100 is administered via intravenous infusion in a 3 + 3 study design to identify the maximum tolerated dose (MTD).

Phase:

Phase 1

Details

Lead Sponsor:

Coordination Pharmaceuticals, Inc.

Treatments:

Capecitabine